Foundayo GLP1 Tablet: What the Pill Format Means

Foundayo (orforglipron) is a genuine GLP-1 weight loss tablet: a once-daily swallowed oral medicine authorised in the UK for chronic weight management and type 2 diabetes, rather than an injection. It works by activating the same GLP-1 pathway as injectable treatments, a natural hormone released by the gut after eating that helps regulate appetite and blood sugar levels, but the tablet format changes several practical things worth understanding before you consider it.

For adults in the UK looking at prescription options to support weight loss or manage type 2 diabetes, especially if you want a needle-free alternative to weight loss injections, the details matter. This guide focuses on what Foundayo is, how the tablet differs from injections, who may be eligible, how private prescription access works in the UK, and the practical points around dosing, availability, and what to ask before starting.

Key things to know

• Foundayo is a once-daily swallowed tablet, not an injection
• It is a small-molecule, non-peptide GLP-1 medicine, with no fasting or water restrictions
• It is genuinely available on private prescription in the UK since 24 August 2026, following MHRA approval on 10 August 2026
• The weight-loss results cannot be directly compared with injectable GLP-1 medicines because they have not been tested head-to-head in the same weight-management trial.

Is Foundayo Genuinely a Pill?

Yes. Foundayo (orforglipron) is a swallowed tablet taken once daily, at any time of day, without food or water restrictions. It is a small-molecule, non-peptide GLP-1 receptor agonist.Its small-molecule, non-peptide structure allows it to be developed as an oral GLP-1 medicine without the administration restrictions associated with peptide-based oral treatments.

What Being a Tablet Genuinely Changes

• No needles, no injection technique to learn
• No weekly schedule to remember, taken daily instead
• No specific fasting or water requirements, unlike some other oral GLP-1 tablets
• It does not require special temperature storage conditions

These are genuine, practical advantages for people who find injections difficult, or who simply prefer a tablet-based routine.

Tablet vs Injection: The Genuine Trade-Off

The 11.2% figure is the treatment-regimen result from ATTAIN-1. Results from separate trials should not be treated as a direct comparison.

There's no published head-to-head trial directly comparing Foundayo against Mounjaro in the same study population, so this is a general guide based on each medicine's own separate trial data, not a precise, like-for-like comparison. The weight-loss results cannot be directly compared with injectable GLP-1 medicines because they have not been tested head-to-head in the same weight-management trial.

Is the Foundayo Pill Available in the UK?

Yes. The MHRA authorised Foundayo (orforglipron) on 10 August 2026, making the UK the first country in Europe to authorise it. Foundayo became available through private prescription in the UK on 24 August 2026. It is a prescription-only medicine and is not currently funded by the NHS.

Who Is the Foundayo Tablet Licensed For?

• Adults with a BMI of 30 or above, for weight management
• Adults with a BMI of 27 to 30 with at least one weight-related health condition
• Adults with insufficiently controlled type 2 diabetes, to improve blood sugar control

How to Access the Foundayo Tablet

Foundayo is a prescription-only medicine. Genuine access requires an online consultation with UK-registered prescribers to confirm your eligibility and suitability, the same clinical assessment process used for other GLP-1 medicines.

Medical Disclaimer

This page provides general information about Foundayo (orforglipron) as an oral GLP-1 tablet. It is not a substitute for personalised medical advice, diagnosis, or treatment. Suitability depends on an individual clinical assessment. Speak to a suitably qualified healthcare professional to determine whether Foundayo is right for you.